| Ytd | -21.28% | |
| 1y | 80.49% |
| Open | 7.40 | Prev Close | 7.48 | Low | 7.38 | High | 7.54 | Mkt Cap | 327.56M |
| Vol | 67.73K | Avg Vol | 1.18M | EPS | -3.28 | P/E | -2.28 | Forward P/E | -1.00 |
| Beta | 1.87 | Short Ratio | 7.35 | Inst. Own | 76.11% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 8.53 | 200-d Avg | 8.23 | 1yr Est | 27.33 |
KYTX News
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Kyverna Therapeutics (NASDAQ:KYTX)
Majority of patients met the American College of Rheumatology improvement criteria (ACR70) response
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Kyverna Therapeutics (NASDAQ:KYTX) w
JP Morgan analyst Brian Cheng maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Overweight and
Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(0.66) per share which beat the ana
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Kyverna Therapeutics (NASDAQ:KYTX)
Kyverna Therapeutics Inc (NASDAQ: KYTX) shares rose 25.8% in pre-market trading after positive trial
Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability sco
Kyverna Therapeutics Inc. shares surged 24% after hours following positive registrational trial resu
Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(0.80) per share which beat the ana
